Use Of “Omics” Technologies For Mechanistic Understandings Of Toxicological Events | 34546
ISSN: 2155-9872

Journal of Analytical & Bioanalytical Techniques
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google scholar citation report
Citations : 3463

Journal of Analytical & Bioanalytical Techniques received 3463 citations as per google scholar report

Journal of Analytical & Bioanalytical Techniques peer review process verified at publons
Indexed In
  • CAS Source Index (CASSI)
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Directory of Research Journal Indexing (DRJI)
  • Hamdard University
  • OCLC- WorldCat
  • Scholarsteer
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Euro Pub
Share This Page

Use of “Omics” technologies for mechanistic understandings of toxicological events

6th International Conference and Exhibition on Analytical & Bioanalytical Techniques

Toshinori Yamamoto

RaQualia Pharma Inc., Japan

ScientificTracks Abstracts-Workshop: J Anal Bioanal Tech

DOI: 10.4172/2155-9872.S1.021

Drug toxicity observed in pre-/non-clinical animal studies sometimes leads to discontinuation of drug candidates. Understanding the phenomena or backgrounds surrounding toxicological events occurred must be a key element for attrition improvement in research and development (R&D) of new chemical entities (NCEs), often requiring mechanistic investigations to understand toxicological mechanism of actions and then to make “Go” or “No go” decisions. In the post-genomic era, a battery of “Omics” technologies was introduced and has been rapidly increasing utilization, among which is the prefix of “toxico-” added to each omics technology in toxicology field. Especially, metabolomics in toxicology, which is so-called “toxicometabolomics”, has been widely implemented in this area. The objectives are to identify and characterize the metabolites, both endogenous and exogenous, which are the end products of cellular metabolism and drug metabolism, respectively. Moreover, toxicometabolomics enables to capture the phenotypic changes in the events, which are generated by enzymatic proteins as resultants of gene expression, at the molecular level; therefore, smooth translation of the findings can be made into the clinic. The presentation in this session will review the usefulness of toxicometabolomics technologies which are generally nuclear magnetic resonance (NMR)-based and mass spectrometry (MS)- based, and other toxic-Omics technologies. Furthermore, today, newly introduced technology, MS imaging (MSI) is considered applicable in the toxicology field, hence its toxicological usability will be also reviewed.

Toshinori Yamamoto, PhD is currently VP and Head of Preclinical Research, RaQualia Pharma, Japan. He experienced broad range of Pharmaceutical R&D covering Discovery through Regulatory Filing, wherein mainly focusing on DMPK, toxicology and clinical development for more than 20 years. Before joining RaQualia in 2008, he worked at Chugai Pharmaceuticals and Pfizer, Japan. He was a visiting researcher at the University of Arizona and the University of Michigan. He was awarded the 2010 Incentive Award from the Japanese Society of Toxicology (JSOT), and the JSOT Tanabe Award in 2006, 2007 and 2008.

Email: [email protected]